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IL-10a b s t r a c t
Leishmaniasis’ treatment is based mostly on pentavalent antimonials or amphotericin B long-term
administration, expensive drugs associated with severe side effects. Considering these aforementioned,
the search for alternative effective and safe leishmaniasis treatments is a necessity. This work evaluated
a neolignan, licarin A anti-leishmanial activity chemically synthesized by our study group. It was
observed that licarin A effectively inhibited Leishmania (Leishmania) major promastigotes (IC50 of
9.59 ± 0.94 lg/mL) growth, by inducing in these parasites genomic DNA fragmentation in a typical death
pattern by apoptosis. Additionally, the neolignan proved to be even more active against intracellular
amastigotes of the parasite (EC50 of 4.71 ± 0.29 lg/mL), and signiﬁcantly more effective than meglumine
antimoniate (EC50 of 216.2 ± 76.7 lg/mL) used as reference drug. The antiamastigote activity is associated
with an immunomodulatory activity, since treatment with licarin A of the infected macrophages induced
a decrease in the interleukin (IL)-6 and IL-10 production. This study demonstrates for the ﬁrst time the
antileishmanial activity of licarin A and suggests that the compound may be a promising in the develop-
ment of a new leishmanicidal agent.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Leishmaniasis, an infectious parasitic diseases complex is
caused by protozoans from Leishmania genus. These diseases are
included in the neglected tropical diseases (NTD) group. NTD are
chronic infections that are most common in countries with unfa-
vorable socioeconomic conditions (Feasey et al., 2010; WHO,
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iasis is endemic in 88 tropical and subtropical countries, where it is
estimated that about 12 million of people are already infected with
these parasites, with incidence of 2 million new cases per year, and
approximately 350 million of people live in risk areas (WHO,
2010).
Leishmaniasis is characterized by a spectrum of clinical mani-
festations ranging from simple ulcerative skin lesions to disﬁguring
mucocutaneous forms, and visceral forms that can be fatal if not
treated (Murray et al., 2005; David and Craft, 2009). In the last
60 years the pentavalent antimonials such as meglumine antimo-
niate (Glucantime) and sodium stibogluconate (Pentostan) have
been used as the ﬁrst-line treatment for all forms of leishmaniasis
(Balaña-Fouce et al., 1998; Croft et al., 2006). However, these drugs
have several limitations and disadvantages such as painful paren-
teral administration, high cost, long-term treatment, and serious
side effects which include hepato- and cardiotoxicity (Balaña-
Fouce et al., 1998; Croft et al., 2006). In refractory cases, second line
drugs such as amphotericin B and pentamidine are used. However,
these drugs also present high toxicity (Balaña-Fouce et al., 1998;
Croft et al., 2006). Thus, the search for new antileishmanial drugs
that are more effective against parasite and exhibit low toxicity
to the host is a matter of dire necessity.
Neolignans are plants secondary metabolites, usually dimers
formed through the oxidative coupling of allyl and propenylphe-
nols, either through intermonomer linkages or crossed-linkages
(Barbosa-Filho, 2004). Several biological and pharmacological ef-
fects have been reported for this class of secondary metabolites,
including antitumoral (Lee et al., 2004; Kang et al., 2012), antimi-
crobial (León-Díaz et al., 2010), trypanocidal (Cabral et al., 2010;
Pelizzaro-Rocha et al., 2011), antileishmanial (Aveniente et al.,
2007; Vendrametto et al., 2010) and antimalarial (Zhang et al.,
2001) activities among others. Licarin A is a neolignan originally
isolated from plants (Barbosa-Filho et al., 1989) but it chemical
synthesis is feasible (Chioccara et al., 1993; Nascimento et al.,
2000). Licarin A presents several biological activities, among which
is the antiparasitic activity against Trypanosoma cruzi and Schisto-
soma mansoni (Cabral et al., 2010; Pereira et al., 2011). In the pres-
ent study, we investigated antileishmanial activity of licarin A. It
was observed that the neolignan presents antipromastigote activ-
ity associated with fragmentation of the parasites’ DNA and antia-
mastigote activity that correlated well with modulation of cytokine
production by macrophages infected with Leishmania (L.) major.2. Materials and methods
2.1. Parasites
Promastigote forms of L. (L.)major (MHOM/IL/1980/FN) used in
this work were generously provided by Dr. Maria Norma Melo
(Laboratório de Biologia de Leishmania – Instituto de Ciências
Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte,
Brazil). The culture was maintained in vitro at 25 ± 1 C in test
tubes containing biphasic culture medium, consisting of a solid
medium agar-blood ‘‘Novy-MacNeal and Nicolle’’ (NNN) and
Schneider medium (Sigma–Aldrich™, St. Louis, USA) supplemented
with 20% fetal bovine serum (FBS) (Cultilab, São Paulo, Brazil),Fig. 1. Chemical structure of neolignan licarin A.streptomycin (100 lg/ml) and penicillin (100 U.I/mL) (Cultilab,
São Paulo, Brazil) (Jacob et al., 2013). The parasites were main-
tained in vivo in Balb/c mice infected in the left hind paw.
2.2. Licarin A and commercial drugs
Licarin A (Fig. 1) was synthesized by our study group according
to our patent application PI 1101946-8, dealing with ‘‘Biocatalyst
oxidative process using coconut water from Cocos nucifera as med-
ium reaction and peroxidase source’’. The licarin A was subjected
to nuclear magnetic resonance (NMR) of 1H e 13C for identiﬁcation,
and was identiﬁed as the enantiomer ()-licarin A. Yield: 60%; m.p.
108 C (CHCl3). aD25 = 20 (CHCl3; c 1,0). 1H-NMR (d, 200 MHz,
CDCl3): 6,96 (1H, s, H60), 6,88 (2H, sl, H20eH50), 6,77 (1H, sl, H6),
6,75 (1H, sl, H2), 6,36 (1H, d, Ha, J = 15,7), 6,09 (1H, dq, Hb,
J = 15,7 e 6,6 Hz), 5,64 (1H, s, OH), 5,08 (1H, d, Ha0, J = 9,5 Hz,),
3,88 (3H, s, OCH3), 3,86 (3H, s, OCH3), 3,43 (1H, dq, Hb0, J = 9,5 e
6,8 Hz), 1,86 (3H, dd, Hl, J = 6,6 e 1,7 Hz), 1,36 (3H, d, Hl0,
J = 6,8 Hz). 13C- NMR (d, 50,3 MHz, CDCl3): 146,60 (C4),146,48
(C50), 145,70 (C5), 144,08 (C40), 133,20 (C3), 132,13 (C10), 132,00
(C1), 130,87 (Ca), 123,44 (Cb), 119,93 (C20), 114,00 (C30), 113,23
(C2), 109,10 (C6), 108,83 (C60), 93,72 (Ca0), 55,89 (OMe), 45,60
(Cb0), 18,39 (Cl), 17,50 (Cl0). The data obtained was in concordance
with the literature (Barbosa-Filho et al., 1989; Pereira et al., 2011)
The neolignan obtained was diluted in DMSO (Sigma–Aldrich™,
St Louis, USA) to prepare a 20 mg/mL stock solution. For each
experiment, working solutions (0.1% DMSO) were prepared by
diluting the stock solution in culture medium. We used as refer-
ence drugs the pentavalent antimony (Sbv) meglumine antimoni-
ate (Glucantime – Aventis Pharma™, SP, Brazil) and
amphotericin B (Cristália, SP, Brazil).
2.3. Animals
Female Balb/c mice (8–10 weeks) obtained from Keizo Asami
Immunopathology Laboratory (Universidade Federal de Pernam-
buco, Recife, Brazil) and female Swiss mice (Mus musculus)
(8–10 weeks) obtained from Professor Thomas George Animal
House (Centro de Biotecnologia, Universidade Federal da Paraíba,
João Pessoa, Brazil) were used. All animals were kept in an environ-
ment with temperature controlled at 21 ± 2 C, light and dark cy-
cles of 12/12 h and had free access to food and water. All
experimental protocols were previously approved by the Ethics
Committee for Animal Research (CEPA) of Universidade Federal
da Paraíba (case number 0410/10).
2.4. Antipromastigote activity of licarin A
The sensitivity of L. (L.) major promastigotes to licarin
A, amphotericin B and meglumine antimoniate was evaluated as
previously described (Amorim et al., 2013). Brieﬂy, logarithmic
growth phase of L. (L.) major promastigotes (1  106 cells/mL)
were incubated in Schneider medium supplemented with 20%
FBS, streptomycin (100 lg/mL) and penicillin (100 U.I./mL) in the
presence and absence of different concentrations of the substances
evaluated. After 72 h of growth at 25 C, samples were quantiﬁed
in Neubauer chamber under optical microscope. Each experiment
was performed in duplicate and was repeated at least as three
independent experiments. The 50% inhibitory concentration
(IC50) was calculated by Probit analysis (SPSS for Windows 8.0).
2.5. DNA fragmentation analysis
For DNA fragmentation analysis, logarithmic growth-phase of
L. (L.) major promastigoteswere treatedwith different licarin A con-
centrations for six hours at 25 ± 1 C. In parallel the promastigotes
Fig. 2. L. (L.) major promastigotes growth inhibition in the presence of different
licarin A, amphotericin B and meglumine antimoniate concentrations. The graph
represents the mean ± S.E.M. of at least three independent experiments performed
in duplicate. ⁄P 6 0,05; ⁄⁄P 6 0,01; ⁄⁄⁄P 6 0,001.
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fragmentation in promastigotes of Leishmania sp. (Das et al., 2001).
These parasites were subjected to DNA extraction using chloro-
form/phenol method (Sambrook et al., 1989). The DNA samples
were analyzed in agarose gels (2%) stained with ethidium bromide,
and the electrophoresis was performed for 1.5 h at 60 mV. The re-
sult was visualized using a UV transilluminator (ImageMaster).
2.6. Peritoneal macrophages isolation
Peritoneal macrophages from Swiss and Balb/c mice were iso-
lated as described by Oliveira et al. (2005). Brieﬂy, mice were elic-
ited with 1 mL of thioglycolate (3%) injected intraperitoneally.
After 5 days, animals were euthanized by cervical dislocation and
the peritoneal cavity was washed with 10 mL of PBS (phosphate
buffer saline pH: 7.4) supplemented with FBS (3%) to obtain the
macrophages. The cells were centrifuged for 10 min at 111g and
suspension was adjusted with RPMI 1640 medium (Cultilab, SP,
Brazil) supplemented with 10% FBS.
2.7. Cytotoxicity assay and selectivity index determination
Licarin A cytotoxicity was evaluated against Swiss mice perito-
neal macrophages using the colorimetric assay of 3-(4,5-dimethyl-
thiazol-2-yl) -2,5-difeniltetrazolium bromide (MTT) (Mosman,
1983) and dye exclusion assay trypan blue vital (Freshney, 1994)
as performed by Monte Neto et al. (2008). Brieﬂy, for MTT analysis,
murine peritoneal macrophages (4  105 cells/200 lL) were incu-
bated in 96-well plates in the presence or absence of licarin A at
37 C in a 5% CO2 atmosphere for 24 h. Then, MTT (5 mg/mL) was
added in each well and after 4 h, 10% sodium dodecyl sulfate
(SDS) was added. The results were analyzed on spectrophotometer
at 540 nm. For trypan blue viability dye assay, murine peritoneal
macrophages (1  106 cells/mL) were incubated in polypropylene
tubes in the neolignana presence or absence. After 24 h at 37 C
in 5% CO2 atmosphere, cells were quantiﬁed in Neaubauer chamber
with 0.4% trypan blue. Viability of the cells exposed to licarin A was
determined by comparing the culture with control (no drug). Each
experiment was performed in duplicate, with at least three inde-
pendent experiments. The concentration that caused a 50% reduc-
tion in cell viability (CC50) was calculated by Probit analysis (SPSS
for Windows 8.0). The selectivity index (SI) was calculated by
dividing the CC50 for peritoneal macrophages by IC50 for L. (L.) ma-
jor promastigote forms (Amorim et al., 2013).
2.8. Licarin A activity against intracellular amastigotes
Macrophages infected with L. (L.) major treatment was per-
formed as described by Amorim et al. (2013). Brieﬂy, peritoneal
macrophages from Balb/c mice (5  105 cells/mL) were incubated
in 24-well plates for 2 h at 37 C and 5% CO2, and then infected
with stationary growth-phase of L. major promastigotes (5  106
cells/mL) in the ratio of 10 promastigotes: 1 macrophage. After
3 h of infection, each well was washed three times with pre-
warmed RPMI 1640 medium to remove non-ingested promastig-
otes and fresh mediumwas added. The infected macrophages were
treated with different concentrations of licarin A or meglumine
antimoniate, used as a positive control, for 24 and 72 h. About
300 macrophages were analyzed in each stained coverslip under
light microscopy. Each experiment was performed in duplicate
and repeated at least three times. The survival index was deter-
mined by multiplying the number of infected macrophages and
the number of amastigotes per infected macrophage (Vendrametto
et al., 2010). These values were used to determine the 50% effective
concentration (EC50) of licarin A by Probit analysis (SPSS for
Windows 8.0).2.9. Cytokines and nitric oxide production
The supernatant obtained from the antiamastigote assays were
stored at 20 C for TNF-a, IL-6, IL-10 and nitric oxide (NO) pro-
duction analysis. Cytokines determination was performed by sand-
wich ELISA assay according to manufacturer’s instructions
(eBioscience™, USA). Supernatants were also evaluated for nitrite
production by the Griess reaction as a measure of NO production
(Green et al., 1982). The cytokines limit detection varied from 7
to 1000 pg/mL for TNF- a and IL-6 and from 31 to 4000 pg/mL
for IL-10.2.10. Statistical analysis
The data obtained were presented as mean ± standard error of
the mean (S.E.M.). Student’s t-test was used to evaluate the indi-
vidual data signiﬁcance, and one-way analysis of variance (ANO-
VA) for comparison between groups. For statistical analysis
GraphPadPrism software version 5.0 for Windows (GraphPad Soft-
ware, San Diego, CA, USA) was used. Only values of P 6 0.05 were
considered as signiﬁcant.3. Results
3.1. Licarin A presents antipromastigote activity associated with DNA
fragmentation
In order to determine licarin A effect against L. (L.) major pro-
mastigote forms, parasite growth inhibition in the presence of
the neolignan was analyzed (Fig. 2). Licarin A inhibited L. (L.) major
promastigotes growth at all concentrations analyzed, resulting in
IC50 of 9.59 ± 0.94 lg/mL (29.38 ± 2.88 lM). In parallel, the refer-
ence drugs meglumine antimony (Sbv) and amphotericin B were
also analyzed. It was found that the Sbv inhibited the promastig-
otes growth only at high concentrations (IC50 > 8.0 mg/mL). On
the contrary, amphotericin B inhibited L. (L.) major promastigotes
growth as little as from 0.05 lg/mL concentration, resulting in an
IC50 of 0.13 ± 0.008 lg/mL.
In order to investigate the mechanisms associated with the
antipromastigote activity of licarin A, we analyzed if this neolignan
could be inducing cell death by apoptosis. Licarin A was found to
induce L. (L.) major promastigotes genomic DNA fragmentation
after 6 h of exposure to 4 and 8 times of its IC50 concentration
Fig. 3. L. (L.) major promastigotes genomic DNA treated with different licarin A
concentrations or H2O2 4 mM. The agarose gel (2%) was stained with ethidium
bromide (0.25 lg/ml) and the analysis was performed under UV light. (M)
molecular marker 1 kb DNA (1) control; (2) H2O2 4 mM (positive control); Licarin
A at concentrations of IC50 (3), 2 IC50 (4), 4 IC50 (5) e 8 IC50 (6).
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parasites with hydrogen peroxide (H2O2) at 4 mM, used as positive
control of cell death by apoptosis.3.2. Licarin A cytotoxicity and selectivity index
Licarin A cytotoxicity on murine macrophages analysis was
investigated (Fig. 4) by trypan blue exclusion assay (Fig. 4a) and
MTT reduction method (Fig. 4b). Licarin A cytotoxicity tests re-
vealed that there was no observed change in cell viability at upFig. 4. Licarin A cytotoxicity on Swiss mice peritoneal macrophages. Cell viability
was assessed by trypan blue exclusion assay (a) and by MTT reduction method (b).
The graph represents the mean ± S.E.M. of at least three independent experiments
performed in duplicate. ⁄P 6 0.05; ⁄⁄P 6 0.01.to 400 lg/mL concentration by the MTT reduction method
(Fig. 4b). A signiﬁcant reduction in cell viability was only observed
at 800 lg/mL concentration, resulting in a CC50 of 729.80 lg/mL.
These values were used to calculate the selectivity index, thus
obtaining a value of 76.10. Licarin A cytotoxicity assessed by try-
pan blue exclusion assay gave 308.96 lg/mL as CC50 (Fig. 4a),
which resulted in a selectivity index of 32.21.3.3. Licarin A antiamastigote activity on macrophage infected with L.
(L.) major
To evaluate the antiamastigote activity, murine macrophages
infected in vitro with L. (L.) major were exposed to licarin A
(Fig. 5). The treatment for 24 h with the neolignan induced a sur-
vival index decrease of macrophages infected with L. (L.) major
for both concentrations analyzed (Fig. 5a). After 72 h of exposure
we observed an even greater reduction in the survival index,
resulting in an EC50 of 4.71 ± 0.29 lg/mL (Fig. 5b). In parallel, the
reference drug meglumine antimoniate (Sbv) was only able to in-
duce a signiﬁcant reduction in the survival index at 200 lg/mL,
after both periods of treatment evaluated. Thus, the EC50 of Sbv
was calculated to be 216.2 ± 76.7 lg/mL after 72 h of treatment.3.4. Cytokines and nitric oxide production
To evaluate possible immunomodulatory activity of licarin A on
macrophages infected with L. (L.) major, the levels of TNF-a, IL-6,
IL-10 and NO were measured in the supernatant of infected macro-
phages (Fig. 6). We observed that treatment with the neolignan doFig. 5. Survival index of macrophages infected with L. (L.) major. The macrophages
were infected with L. (L.) major and treated with licarin A or meglumine
antimoniate for 24 h (a) and 72 h (b). The graph represents the mean ± S.E.M. of
at least three independent experiments performed in duplicate. ⁄P 6 0.05;
⁄⁄P 6 0.01.
Fig. 6. Licarin A effect in TNF-a (a), IL-6 (b), IL-10 (c) and NO (d) production. The cytokines and NO concentrations were measured in the supernatants culture of macrophages
infected with L. (L.)major and treated with licarin A for 24 h or 72 h. The graph represents the mean ± S.E.M. of at least three independent experiments performed in duplicate.
⁄P 6 0.05.
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(Fig. 6b) and IL-10 (Fig. 6c) were reduced after treatment with
20 lg/mL of licarin A. NO levels were not affected after different
treatments with licarin A (Fig. 6d).
4. Discussion
Drugs commonly used in the treatment of leishmaniasis, such
as pentavalent antimonials and amphotericin B, are parenterally
administered drugs which have high toxicity (Balaña-Fouce et al.,
1998 Croft et al., 2006), requiring in many cases hospitalization
of the patient, which makes this treatment very expensive. Thus,
researches aimed at obtaining alternative treatments for these dis-
eases are warranted.
Licarin A is a neolignan isolated from several plant species
(Barbosa-Filho et al., 1989; Barros et al., 2009) but its chemical syn-
thesis is also viable (Chioccara et al., 1993; Nascimento et al.,
2000). Given the poor yield of licarin A isolation from plants (Barb-
osa-Filho et al., 1989), the possibility of chemical synthesis is a via-
ble solution for the production of this neolignan in satisfactory
quantity. In this context, licarin A used in the present study was
synthesized by our study group through a methodology using
Cocos nucifera coconut water as reaction medium and source of
peroxidase according to our patent application PI 1101946-8
(manuscript in preparation). This synthesis demonstrates the eco-
nomic viability, not only due to the use of an abundant natural
source of peroxidase, but also to because it presents good yield
and have stereoselectivity, producing mainly the ()-licarin A
enantiomer.
In the searching for new molecules with anti-leishmanial activ-
ity, this study demonstrated that licarin A presents in vitro activity
against L. (L.) major. The results show that licarin A has adose-dependent effect on the promastigotes growth of L. (L.) major.
The IC50 value presented by the neolignan demonstrated that it is
more active than the reference drug, meglumine antimoniate
(Sbv). However, available information from literature show that
Sbv has lower toxic action against Leishmania promastigotes forms
compared with the amastigotes forms (Ephros et al., 1999; Ver-
meersch et al., 2009). It was observed that amphotericin B was
more effective than licarin A against L. (L.) major promastigotes.
Although this antifungal is used as second-line drug in leishmani-
asis treatment, it has been reported to be highly toxic with serious
associated side effects, such as nephrotoxicity (Balaña-Fouce et al.,
1998).
Previous studies have shown that licarin A has several impor-
tant pharmacological properties, among them the antimicrobial
activity against multidrug resistant Mycobacteria (León-Díaz
et al., 2010), cytotoxic and antiproliferative effect on human cancer
cell lines (Lee et al., 2004; Park et al., 2004), schistosomicidal effect
(Pereira et al., 2011) and trypanocidal activity (Cabral et al., 2010;
Pereira et al., 2011). Considering licarin A antiparasitic activity, we
noted that the trypanocidal activity observed against T. cruzi try-
pomastigotes for the enantiomer ()-licarin A (IC50/24 h 23 lM)
(Pereira et al., 2011) was similar to the anti-leishmanial effect
investigated in this study on L. (L.) major promastigotes (IC50/
72 h 29.38 ± 2.88 lM). However, comparing our antipromastigote
results with those of Cabral et al. (2010) on T. cruzi epimastigotes
(IC50/96 h 462.7 lM) and trypomastigotes (IC50/24 h 960 lM),
these data seem to suggest that licarin A presents a greater
in vitro anti-leishmanial than trypanocidal activity. Nevertheless,
Cabral et al. (2010) did not report in their work the type of licarin
A enantiomer used for tests against T. cruzi parasites.
The induction of programmed cell death (apoptosis) in para-
sites, such as if Leishmania species is associated with mechanism
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(SbIII) (Sudhandiran and Shaha, 2003), amphotericin B (Lee et al.,
2002) and miltefosine (Paris et al., 2004). In this context, genomic
DNA fragmentation is one of the typical characteristics of cells
undergoing apoptosis that occurs both in the metazoans (Stewart,
1994) as well as in the unicellular organisms (Das et al., 2001;
Ardestani et al., 2012), in response to an inductor stimulus. The re-
sults obtained here demonstrate that treatment of L. (L.) major
promastigotes with licarin A induced genomic DNA fragmentation
ladder similar to that seen after treatment with hydrogen peroxide
(4 mM), which is typical of apoptotic cells (Das et al., 2001).
One of the limitations of drugs used in leishmaniasis treatment
is the problem of high toxicity (Balaña-Fouce et al., 1998; Croft
et al., 2006). In the course of search for new effective and save
drugs, some studies have demonstrated a strong correlation be-
tween the results of in vitro cytotoxicity evaluation using mamma-
lian cells and in vivo acute toxicity in animals and humans (Evans
et al., 2001). Thus, licarin A cytotoxicity assay demonstrated that
the neolignan is more toxic to L. (L.) major parasite than to macro-
phages, the host cells of the amastigotes form. The trypan blue
exclusion test, which evaluates cell membrane integrity, seems
to be more sensitive in the cytotoxicity analysis than the MTT
reduction colorimetric assay, as previously observed (Monte Neto
et al., 2008). While MTT reduction assay measures the succinate
dehydrogenase mitochondrial enzyme activity (Mosmann, 1983),
the trypan blue exclusion test evaluates possible damage of licarin
A to the plasma membrane integrity which may results in cell
death (Freshney, 1994). Thus, the observed difference in the results
of the in vitro cytotoxicity assay can partly be explained due to the
difference in the methodological principles used. Additionally,
other factor that may inﬂuence the differences in the cytotoxicity
results is that in trypan blue tests the cells were in suspension
and, therefore, presented a greater surface area of contact with
the drug in comparison to MTT assay, in which cells adhered to
plates. Nevertheless, considering the more sensitive of the assay,
licarin A was approximately 32 times more toxic to L. major prom-
astigotes than to the murine macrophages, demonstrating a high
selectivity index. The low licarin A cytotoxicity against murine
macrophages has also been reported by Cabral et al. (2010).
To evaluate the drug effect on the amastigotes, which is the
stage present in vertebrate hosts, macrophages were infected with
L. (L.) major and subsequently treated with the neolignan. Licarin A
showed a signiﬁcant antiamastigote activity, being able to reduce
the survival index of intracellular amastigotes at non toxic concen-
trations for the host cell. On analyzing the EC50 value of licarin A, it
was noted that the concentration required was approximately
45 times lower than the concentration required to reduce by 50%
the survival index of the intracellular amastigotes when compared
to meglumine antimoniate (Sbv), after 72 h of treatment. These re-
sults demonstrate that the neolignan is more effective in the treat-
ment of the macrophages infected with L. (L.) major than the Sbv
(P < 0.025), one of the ﬁrst-line drug in leishmaniasis treatment
(Balaña-Fouce et al., 1998; Croft et al., 2006).
The comparative analysis of licarin A anti-leishmanial activity
shows that L. (L.) major intracellular amastigotes were more sensi-
tive (EC50/72 h 4.71 ± 0.29 lg/mL) to the neolignan than the pro-
mastigote forms (IC50/72 h 9.59 ± 0.94 lg/mL) (P < 0.0039). Thus,
the antiamastigote activity observed can be because of the drug di-
rect action on the parasite as well as an indirect action, through
induction of the macrophages activation to contain the infection.
To analyze this possible immunomodulatory effect, production of
TNF-a, IL-6 and IL-10 and nitric oxide by the infected macrophages
L. (L.) major exposed to the neolignan was evaluated.
It is reported in literature that resistance to infection with L. (L.)
major in inbred mice is related to a Th1-type immune response,
which secretes cytokines such as IFN-c and TNF-a resulting inmacrophage activation and ultimately parasites death (Sacks and
Noben-Trauth, 2002; Vila-del Sol et al., 2007). On the other hand,
a Th2 response development, with cytokines production such as
IL-4, IL-10 and TGF-b, contributes to L. (L.) major infected mice sus-
ceptibility due to a down regulation of Th1 cell differentiation and
macrophage activation suppression (Sacks and Noben-Trauth,
2002). Among the oxygen metabolites toxic to Leishmania pro-
duced by activated macrophages are the superoxide anion (O2),
hydrogen peroxide (H2O2), and especially nitric oxide (NO) (Liew
et al., 1990; Vila-Del Sol et al., 2007).
In the present work it was observed that licarin A antiamasti-
gote activity is associated with a decrease in IL-6 and IL-10 produc-
tion. Previous studies demonstrated that IL-6 participates in the
differentiation of CD4+cells into Th2 cells by inducing the IL-4 pro-
duction, and inhibiting the signaling pathway of IFN-c, preventing
a Th1 response formation (Rincón et al., 1997; Diehl et al., 2000).
This cytokine also inhibits, in vitro, anti-leishmanial activity in-
duced by TNF-a and IFN-c on macrophages infected with L. (L.)
amazonensis (Hatzigeorgiou et al., 1993), and have a suppressive
effect, in vivo, in the containment of L. (L.) donovani liver infection
(Murray, 2008). IL-10 is an anti-inﬂammatory cytokine produced
by various cells types such as macrophages, B lymphocytes, and
various subsets of T lymphocytes (Couper et al., 2008), which
inhibits macrophage activation, and consequently, the leishmani-
cidal activity of these cells (Vouldoukis et al., 1997; Trinchieri,
2001). Therefore, infection containment observed in macrophages
infected with L. (L.) major after treatment with licarin A may be
associated with this immunomodulatory activity, since decreased
levels of IL-6 and IL-10 may be allowing the activation of macro-
phages by TNF-a produced by macrophages, although the TNF-a
levels were not changed signiﬁcantly after treatment with this
neolignan. Furthermore, the antiamastigote activity observed was
independent of NO production.
This work reveals that licarin A presents anti-leishmanial activ-
ity against L. (L.) major promastigote forms, associated with para-
sites DNA fragmentation, suggesting a programmed cell death
mechanism, and on intracellular amastigotes, modulating cytokine
production by host macrophages. Considering the feasibility cou-
pled with the high yield of the licarin A synthesis, this compound
is thus considered promising in the development of a new leish-
manicidal agent.Acknowledgments
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